• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ligand Pharmaceuticals Incorporated - Common Stock (NQ:LGND)

    303.38 +0.81 (+0.27%)
    Streaming Delayed Price Updated: 10:12 AM EDT, Aug 6, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Ligand Pharmaceuticals Incorporated - Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
    From Ligand Pharmaceuticals
    Via GlobeNewswire
    News headline image
    XOMA Royalty Announces Closing of Its Acquisition by Ligand
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
    From XOMA Royalty Corporation
    Via GlobeNewswire
    News headline image
    Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed
    From Orchestra BioMed Holdings, Inc.
    Via GlobeNewswire
    News headline image
    Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Ligand to Present at Stifel 2024 Healthcare Conference
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer
    Mr. Korenberg is a seasoned executive with significant operational and financial leadership experience, including senior roles at Ligand Pharmaceuticals (NASDAQ: LGND) and in healthcare investment... 
    From Palvella Therapeutics
    Via GlobeNewswire
    News headline image
    Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Ligand Reports Second Quarter 2024 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    5 Best Short-Term Stocks to Consider Investing In
    Looking for the best short-term stocks? Explore our top picks and learn how to navigate the risks and opportunities in fast-paced stock trading. 
    Via MarketBeat
    News headline image
    Ligand to Acquire APEIRON Biologics AG for $100 Million
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Lifecore Biomedical Announces Cooperation Agreement with 22NW
    Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board 
    From Lifecore Biomedical, Inc.
    Via GlobeNewswire
    News headline image
    Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Ligand to Participate in Upcoming Investor Conferences
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Ligand Reports First Quarter 2024 Financial Results
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    News headline image
    Ligand to Report First Quarter 2024 Financial Results on May 7, 2024
    From Ligand Pharmaceuticals Incorporated
    Via Business Wire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.